Croakey’s Washington correspondent, Dr Lesley Russell, reports on new research suggesting that researchers and journals are failing their audiences, when it comes to ensuring disclosure of financial ties to industry.
Dr Lesley Russell writes:
A paper published this month on the website of the Archives of Internal Medicine highlights significant failures on the part of researchers to disclose their financial links to the medical industry in their journal articles, and on the part of the publishers to demand this transparency.
The study compared major payments (over US$1 million each) made to researchers/consultants by orthopedic device companies with financial disclosures made subsequently in their articles published in medical journal.
The study was facilitated by disclosures of payments to consultants made by five medical device companies that were forced by government investigations.
These five companies paid out about US$250 million in 2007, with almost half of that going to 41 doctors, 32 of whom wrote or were co-authors on orthopedic journal articles the next year. In the majority of articles the topic was directly related to the company payments.
Of these 32 medical doctors and doctoral researchers, only seven declared their financial interests in every article they published. Eleven researchers made no disclosures at all in the 30 articles they published.
One of the authors of the study described their findings as representing “massive, dramatic system failure”.
Dr Marcia Angell, a former editor of the New England Journal of Medicine said that the study was “one more indication of the widespread corruption of the medical profession by industry money.”
“The journals’ lax enforcement of disclosure policies probably reflects the fact that journals too are dependent on industry support,” she said.
The International Committee of Medical Journal Editors has recently proposed better disclosure policies, but each journal sets its own policy, and clearly some have not done a good job of this.
The recently enacted health care reform legislation will facilitate more of these sorts of disclosures through the stringent “sunshine” provisions that are part of the new law.
Beginning in 2013, the law requires pharmaceutical and device companies to disclose payments (including those made in kind) to doctors, and these disclosures will be available in a national on-line database. The database will include the name, address and specialty of the recipient, the value of the payment, the date it was made, the reason for the payment and the product to which it was linked.
• Dr Lesley Russell is the Menzies Foundation Fellow at the Menzies Center for Health Policy, University of Sydney/ Australian National University and a Research Associate at the US Studies Centre, University of Sydney. She is currently a Visiting Fellow at the Center for American Progress in Washington DC.